Moksifloksacin
(Preusmjereno sa stranice FABPRXSRWADJSP-MEDUHNTESA-N)
| |||
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| 7-[(4aS,7aS)-oktahidro-1H-pirolo[3,4-b]piridin-6-il]-1-ciklopropil-6-fluoro-8-metoksi-4-okso-1,4-dihidrohinolin-3-karboksilna kiselina | |||
| Klinički podaci | |||
| Robne marke | Avelox, Avelox I.V., Vigamox | ||
| AHFS/Drugs.com | Monografija | ||
| Identifikatori | |||
| CAS broj | 354812-41-2 | ||
| ATC kod | J01MA14 , S01AE07 | ||
| PubChem[1][2] | 152946 | ||
| DrugBank | DB00218 | ||
| ChemSpider[3] | 134802 | ||
| KEGG[4] | C07663 
| ||
| Hemijski podaci | |||
| Formula | C21H24FN3O4 | ||
| Mol. masa | 401.4314 | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Fizički podaci | |||
| Tačka topljenja | 238-242 °C (-166 °F) | ||
| Farmakokinetički podaci | |||
| Poluvreme eliminacije | 11,5-15,6 sati | ||
| Izlučivanje | Oko 45% se izlučuje kao nepromenjen lek | ||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
| Način primene | Intravenozno; Oftalmički; Oralno | ||
Moksifloksacin je sintetički fluorohinolonski antibiotski agens. Ovaj lek je razvila kompanija Bajer AG (inicijalno se zvao BAY 12-8039). On je u prodaji širom sveta u obliku hidrohlorida pod imenom Avelox.[5][6][7]
Reference[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub 2003 Nov 4. PMID 14614666
- ↑ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035-41. PMID 21059682.
- ↑ Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Res 36 (Database issue): D901-6. PMID 18048412.
